ReviewInternational journal of nephrology and renovascular disease2014
Management of hemolytic-uremic syndrome in children.
Review in International journal of nephrology and renovascular disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Lung Ultrasound to Evaluate Fluid Status and Optimize Early Volume-Expansion Therapy in Children with Shiga Toxin-Producing Escherichia Coli-Haemolytic Uremic Syndrome: A Pilot Study.Journal of clinical medicine · 2024Article
- Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2023Article
- HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.Pediatric nephrology (Berlin, Germany) · 2023Article
- Evaluation of Six Years of Appropriateness Level of Blood Transfusion in a Pediatric Ward.International journal of environmental research and public health · 2023Article
- How we treat diarrhea in pediatric transplant patients: a brief review.Frontiers in pediatrics · 2023Review
- Adult Shigatoxin-mediated hemolytic uremic syndrome masked by alcohol use and inflammatory bowel disease.BMJ case reports · 2021Article
- Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-ProducingFrontiers in cellular and infection microbiology · 2021Review
- C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Low C3 Serum Levels Predict Severe Forms of STEC-HUS With Neurologic Involvement.Frontiers in medicine · 2020Article
- Structural and Functional Characterization of Stx2k, a New Subtype of Shiga Toxin 2.Microorganisms · 2019Article
- Antimicrobial Resistance in Class 1 Integron-Positive Shiga Toxin-ProducingMicroorganisms · 2018Article
- Case 6: An Infant Presenting with Hematuria and Pallor.Pediatrics in review · 2018Article
- Article
- Blood urea nitrogen to serum creatinine ratio as a prognostic factor in diarrhea-associated hemolytic uremic syndrome: a validation study.European journal of pediatrics · 2018Observational
- Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood.Frontiers in pediatrics · 2018Article
- From Farm to Table: Follow-Up of Shiga Toxin-Producing Escherichia coli Throughout the Pork Production Chain in Argentina.Frontiers in microbiology · 2016Article
- Diminazene aceturate: an antibacterial agent for Shiga-toxin-producingDrug design, development and therapy · 2016Article
- [Advances in differential diagnosis and treatment of thrombotic microangiopathy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Multiplex detection of nine food-borne pathogens by mPCR and capillary electrophoresis after using a universal pre-enrichment medium.Frontiers in microbiology · 2015Article
- A Case ofJournal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute renal failure associated with a fulminant, life-threatening systemic disease is rare in previously healthy young children; however, when it occurs, the most common cause is hemolytic-uremic syndrome (HUS). In most cases (90%), this abrupt and devastating illness is a result of ingestion of food or drink contaminated with pathogens that produce very potent toxins. Currently, there are no proven treatment options that can directly inactivate the toxin or effectively interfere with the cascade of destructive events triggered by the toxin once it gains access to the bloodstream and binds its receptor. However, HUS is self-limited, and effective supportive management during the acute phase is proven to be a life saver for children affected by HUS. A minority of childhood HUS cases, approximately 5%, are caused by various genetic mutations causing uncontrolled activation of the complement system. These children, who used to have a poor prognosis leading to end-stage renal disease, now have access to exciting new treatment options that can preserve kidney function and avoid disease recurrences. This review provides a summary of the current knowledge on the epidemiology, pathophysiology, and clinical presentation of childhood HUS, focusing on a practical approach to best management measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.